DA
AMAG

DSC Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

DSC Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-69,400
Closed -$1.68M – 81
2013
Q4 		$1.68M Buy
+69,400
New +$1.63M 0.82% 29

Other funds holding AMAG

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

DSC Advisors's AMAG Position: Q1 2014 in Review

DSC Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q1 2014, closing a stake of 69,400 shares — an estimated $1.68M sold.

DSC Advisors first reported a position in AMAG in Q4 2013 and held it in 1 quarter. The position peaked at $1.68M in Q4 2013. 102 funds tracked by Wall St. Rank hold AMAG as of Q1 2014.

  • DSC Advisors reported no remaining AMAG Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • DSC Advisors sold 69,400 AMAG Pharmaceuticals shares in Q1 2014, an estimated $1.68M.
  • DSC Advisors first reported a position in AMAG Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • DSC Advisors's AMAG Pharmaceuticals position peaked at $1.68M in Q4 2013.
  • 102 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2014.

Based on DSC Advisors's 13F filing for Q1 2014, filed 15 May 2014.